Jamie Willows
@jamiekwillows.bsky.social
Renal / GIM consultant STSFT, UK. Dad x3. Runner. Poker. PoCUS. #NephJC
Reposted by Jamie Willows
Missing all the overwhelming amount of science coming out of #KidneyWk?
The #NephJC crew has got you covered
Day 2 edition www.nephjc.com/news/kidneyw... via @nephroseeker.medsky.social & moi
The #NephJC crew has got you covered
Day 2 edition www.nephjc.com/news/kidneyw... via @nephroseeker.medsky.social & moi
Kidney Week in Houston: Day 2 — NephJC
in this edition: Fish Oil, GBD, Flozination meta-analysis, CHW intervention in Hispanic/Latino patients, and much more
www.nephjc.com
November 8, 2025 at 2:06 PM
Missing all the overwhelming amount of science coming out of #KidneyWk?
The #NephJC crew has got you covered
Day 2 edition www.nephjc.com/news/kidneyw... via @nephroseeker.medsky.social & moi
The #NephJC crew has got you covered
Day 2 edition www.nephjc.com/news/kidneyw... via @nephroseeker.medsky.social & moi
Reposted by Jamie Willows
Got #KidneyWk FOMO like @nephroseeker.medsky.social ?
We got you covered with daily coverage of the simultaneous publications!
www.nephjc.com/news/kidneyw...
We got you covered with daily coverage of the simultaneous publications!
www.nephjc.com/news/kidneyw...
Kidney Week in Houston: Day 1 — NephJC
in this edition: Atacicept in IgAN; Albuminuria as a surrogate outcome, Renal Remission and additional CONFIDENCE analysis
www.nephjc.com
November 7, 2025 at 5:58 PM
Got #KidneyWk FOMO like @nephroseeker.medsky.social ?
We got you covered with daily coverage of the simultaneous publications!
www.nephjc.com/news/kidneyw...
We got you covered with daily coverage of the simultaneous publications!
www.nephjc.com/news/kidneyw...
Reposted by Jamie Willows
There is some concern about cancers with glipination - thyroid, pancreas, others - nothing seen so far in trials (but rare outcomes are hard to capture)
this study in JAMA Oncology didn't find anything much worrisome jamanetwork.com/journals/jam...
but!
this study in JAMA Oncology didn't find anything much worrisome jamanetwork.com/journals/jam...
but!
September 12, 2025 at 6:51 PM
There is some concern about cancers with glipination - thyroid, pancreas, others - nothing seen so far in trials (but rare outcomes are hard to capture)
this study in JAMA Oncology didn't find anything much worrisome jamanetwork.com/journals/jam...
but!
this study in JAMA Oncology didn't find anything much worrisome jamanetwork.com/journals/jam...
but!
Reposted by Jamie Willows
A study that I have been thinking about a lot is this pilot study/case series
100-200 mg of spiro in diuretic resistant, acute decompensated heart failure looked safe and effective
Any heart failure/diuretic experts know if a larger trial was ever completed?
pubmed.ncbi.nlm.nih.gov/31307058/
100-200 mg of spiro in diuretic resistant, acute decompensated heart failure looked safe and effective
Any heart failure/diuretic experts know if a larger trial was ever completed?
pubmed.ncbi.nlm.nih.gov/31307058/
May 31, 2025 at 1:46 AM
A study that I have been thinking about a lot is this pilot study/case series
100-200 mg of spiro in diuretic resistant, acute decompensated heart failure looked safe and effective
Any heart failure/diuretic experts know if a larger trial was ever completed?
pubmed.ncbi.nlm.nih.gov/31307058/
100-200 mg of spiro in diuretic resistant, acute decompensated heart failure looked safe and effective
Any heart failure/diuretic experts know if a larger trial was ever completed?
pubmed.ncbi.nlm.nih.gov/31307058/
Reposted by Jamie Willows
Always challenged by my occasional (generally intentional) nihilism when it comes to treating frailty & multi morbid patients
#eraedta2025
#eraedta2025
June 4, 2025 at 7:48 AM
Always challenged by my occasional (generally intentional) nihilism when it comes to treating frailty & multi morbid patients
#eraedta2025
#eraedta2025
Reposted by Jamie Willows
Join us tonite 5/13/25 9pm EST only on #Bluesky #NephSky #NephJC
We are discussing 2 studies on the use of desmopressin/ddAVP prophylactically to prevent post kidney biopsy bleeding.
Biopsy Blood🩸, ddAVP Sweat💦 and Nephrologist Tears😢
www.nephjc.com/news/ddavp
We are discussing 2 studies on the use of desmopressin/ddAVP prophylactically to prevent post kidney biopsy bleeding.
Biopsy Blood🩸, ddAVP Sweat💦 and Nephrologist Tears😢
www.nephjc.com/news/ddavp
Double Trouble: ddAVP and the Bleeding Biopsy — NephJC
This week, we will discuss a double header: two single centre ddAVP trials in kidney biopsy from India.
www.nephjc.com
May 13, 2025 at 10:55 AM
Join us tonite 5/13/25 9pm EST only on #Bluesky #NephSky #NephJC
We are discussing 2 studies on the use of desmopressin/ddAVP prophylactically to prevent post kidney biopsy bleeding.
Biopsy Blood🩸, ddAVP Sweat💦 and Nephrologist Tears😢
www.nephjc.com/news/ddavp
We are discussing 2 studies on the use of desmopressin/ddAVP prophylactically to prevent post kidney biopsy bleeding.
Biopsy Blood🩸, ddAVP Sweat💦 and Nephrologist Tears😢
www.nephjc.com/news/ddavp
Reposted by Jamie Willows
Efficacy and safety of finerenone in IgA nephropathy: an observational multicentre study
doi.org/10.1093/ckj/...
doi.org/10.1093/ckj/...
April 30, 2025 at 12:04 PM
Efficacy and safety of finerenone in IgA nephropathy: an observational multicentre study
doi.org/10.1093/ckj/...
doi.org/10.1093/ckj/...
Reposted by Jamie Willows
Physiologically it never made sense to fluid restrict HF patients without hyponatremia. No difference in outcomes in 👇study, which was predictable. At the same time - from a study perspective - the actual difference in fluid intake between groups was <300cc/day.
pubmed.ncbi.nlm.nih.gov/40159556/
pubmed.ncbi.nlm.nih.gov/40159556/
Liberal fluid intake versus fluid restriction in chronic heart failure: a randomized clinical trial - PubMed
Fluid restriction is frequently recommended to patients with chronic heart failure, but randomized clinical trials assessing the effects of fluid restriction remain scarce. In this multicenter open-la...
pubmed.ncbi.nlm.nih.gov
April 1, 2025 at 5:23 AM
Physiologically it never made sense to fluid restrict HF patients without hyponatremia. No difference in outcomes in 👇study, which was predictable. At the same time - from a study perspective - the actual difference in fluid intake between groups was <300cc/day.
pubmed.ncbi.nlm.nih.gov/40159556/
pubmed.ncbi.nlm.nih.gov/40159556/
Reposted by Jamie Willows
Tomorrow night 3/25/25 at 9 pm EST, only on Bluesky #MedSky #NephSky
We will discuss the latest guidance from @kdigo.org on #ADPKD. Topics including screening, cerebral aneurysms, med therapy, KRT, ADPLD and lifestyle recommendations
You have to be there, I in-cyst 🫣
www.nephjc.com/news/adpkd-k...
We will discuss the latest guidance from @kdigo.org on #ADPKD. Topics including screening, cerebral aneurysms, med therapy, KRT, ADPLD and lifestyle recommendations
You have to be there, I in-cyst 🫣
www.nephjc.com/news/adpkd-k...
KDIGO 2025 ADPKD Guidelines Review — NephJC
This week, we will discuss the first iteration of KDIGO’s 2025 guidelines on ADPKD. These guidelines are a result of a decade of global collaboration between physicians, researchers, advocates, ...
www.nephjc.com
March 24, 2025 at 11:53 AM
Tomorrow night 3/25/25 at 9 pm EST, only on Bluesky #MedSky #NephSky
We will discuss the latest guidance from @kdigo.org on #ADPKD. Topics including screening, cerebral aneurysms, med therapy, KRT, ADPLD and lifestyle recommendations
You have to be there, I in-cyst 🫣
www.nephjc.com/news/adpkd-k...
We will discuss the latest guidance from @kdigo.org on #ADPKD. Topics including screening, cerebral aneurysms, med therapy, KRT, ADPLD and lifestyle recommendations
You have to be there, I in-cyst 🫣
www.nephjc.com/news/adpkd-k...
Fantastic opportunity 👇
Announcing the #NephJC internship, @nephjc.bsky.social and @kireports.bsky.social joining forces
www.nephjc.com/intern-app for details and to apply!
#NephSky
www.nephjc.com/intern-app for details and to apply!
#NephSky
NephJC Editorial Internship — NephJC
www.nephjc.com
March 7, 2025 at 3:58 PM
Fantastic opportunity 👇
Reposted by Jamie Willows
Two things, this is finally a small RCT for GLP1 meds and alcohol use disorder. Reductions were noticeable and highlights the need for a big RCT for this.
Secondarily a very small cohort(n=13) who smoked cigarettes also had a reduction in smoking in this study. Lets get more studies on both!
Secondarily a very small cohort(n=13) who smoked cigarettes also had a reduction in smoking in this study. Lets get more studies on both!
From JAMA Psychiatry:
Low-dose semaglutide reduced alcohol craving and consumption in adults with alcohol use disorder.
jamanetwork.com/journals/jam...
Low-dose semaglutide reduced alcohol craving and consumption in adults with alcohol use disorder.
jamanetwork.com/journals/jam...
February 13, 2025 at 3:31 PM
Two things, this is finally a small RCT for GLP1 meds and alcohol use disorder. Reductions were noticeable and highlights the need for a big RCT for this.
Secondarily a very small cohort(n=13) who smoked cigarettes also had a reduction in smoking in this study. Lets get more studies on both!
Secondarily a very small cohort(n=13) who smoked cigarettes also had a reduction in smoking in this study. Lets get more studies on both!
I learned a lot about subclinical primary aldosteronism reading this piece from the unsinkable @brianrifkin.bsky.social 👇
www.nephjc.com/news/primary...
www.nephjc.com/news/primary...
Undercover Aldosterone — NephJC
This week, we will discuss the origins of primary hyperaldosteronism in normotensive patients. Could this undetected anomaly be the cause of idiopathic hypertension and CKD?
www.nephjc.com
February 10, 2025 at 8:52 PM
I learned a lot about subclinical primary aldosteronism reading this piece from the unsinkable @brianrifkin.bsky.social 👇
www.nephjc.com/news/primary...
www.nephjc.com/news/primary...
Reposted by Jamie Willows
Reposted by Jamie Willows
At the second high impact trial session At #ISNWCN
Vlado Perkovic on ziltivekimab in CKD
Covered data on colchicine and Canakinumab (not on market despite CANTOS)
Phase 2 data from RESCUE shows huge effect on hs-CRP
Vlado Perkovic on ziltivekimab in CKD
Covered data on colchicine and Canakinumab (not on market despite CANTOS)
Phase 2 data from RESCUE shows huge effect on hs-CRP
February 9, 2025 at 4:16 AM
At the second high impact trial session At #ISNWCN
Vlado Perkovic on ziltivekimab in CKD
Covered data on colchicine and Canakinumab (not on market despite CANTOS)
Phase 2 data from RESCUE shows huge effect on hs-CRP
Vlado Perkovic on ziltivekimab in CKD
Covered data on colchicine and Canakinumab (not on market despite CANTOS)
Phase 2 data from RESCUE shows huge effect on hs-CRP
Reposted by Jamie Willows
Patient self-directed sliding scale furosemide is an underutilized tool in CHF management
Can a simple weight-based dosing strategy empower patients to manage CHF, prevent exacerbations, and reduce ED visits? Let's dive in! 👇 #medsky #pharmsky #cardiosky #EMsky #GPsky #MedEd 1/
Can a simple weight-based dosing strategy empower patients to manage CHF, prevent exacerbations, and reduce ED visits? Let's dive in! 👇 #medsky #pharmsky #cardiosky #EMsky #GPsky #MedEd 1/
a person is measuring their weight on a scale that goes up to 40
ALT: a person is measuring their weight on a scale that goes up to 40
media.tenor.com
January 31, 2025 at 6:42 AM
Reposted by Jamie Willows
need some bland, meaningless conclusions for your review article?
use these!
these conclusions are so nonspecific that they're perfectly applicable to any ICU topic 👌
you're welcome
use these!
these conclusions are so nonspecific that they're perfectly applicable to any ICU topic 👌
you're welcome
January 28, 2025 at 2:46 PM
need some bland, meaningless conclusions for your review article?
use these!
these conclusions are so nonspecific that they're perfectly applicable to any ICU topic 👌
you're welcome
use these!
these conclusions are so nonspecific that they're perfectly applicable to any ICU topic 👌
you're welcome
Reposted by Jamie Willows
more external validation of the anti-nephrin story
academic.oup.com/ckj/advance-... in @ckj-era.bsky.social
In around 20% MCD - but also some FSGS (suggesting again these arbitrary pathologic descriptors are not useful)
#NephSky
academic.oup.com/ckj/advance-... in @ckj-era.bsky.social
In around 20% MCD - but also some FSGS (suggesting again these arbitrary pathologic descriptors are not useful)
#NephSky
Anti-nephrin antibody: a potential biomarker of minimal change disease
AbstractBackground. Minimal change disease (MCD) is a common pathological type of nephrotic syndrome in children and adults, and the mechanisms remain obsc
academic.oup.com
January 30, 2025 at 6:55 PM
more external validation of the anti-nephrin story
academic.oup.com/ckj/advance-... in @ckj-era.bsky.social
In around 20% MCD - but also some FSGS (suggesting again these arbitrary pathologic descriptors are not useful)
#NephSky
academic.oup.com/ckj/advance-... in @ckj-era.bsky.social
In around 20% MCD - but also some FSGS (suggesting again these arbitrary pathologic descriptors are not useful)
#NephSky
Reposted by Jamie Willows
I like this from Rob Quinn and Pietro Ravani pubmed.ncbi.nlm.nih.gov/24327565/ in @ndt-era.bsky.social to show the various selection biases in most studies of vascular access
#FistulaLast
#FistulaLast
January 30, 2025 at 5:52 PM
I like this from Rob Quinn and Pietro Ravani pubmed.ncbi.nlm.nih.gov/24327565/ in @ndt-era.bsky.social to show the various selection biases in most studies of vascular access
#FistulaLast
#FistulaLast
Reposted by Jamie Willows
BREAKING NEWS: The FDA has approved Ozempic for patients with chronic kidney disease. This means the popular injection can be used to reduce the risk of kidney disease worsening, kidney failure and death from cardiovascular disease in patients with chronic kidney disease and diabetes.
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves a gradual loss of kidney function.
www.cnbc.com
January 28, 2025 at 8:21 PM
BREAKING NEWS: The FDA has approved Ozempic for patients with chronic kidney disease. This means the popular injection can be used to reduce the risk of kidney disease worsening, kidney failure and death from cardiovascular disease in patients with chronic kidney disease and diabetes.
Reposted by Jamie Willows
Finally!
Antibiotics are not non-inferior to appendectomy despite a generous 20% non-inferiority margin
They are actually inferior: www.thelancet.com/journals/lan... in the @thelancet.bsky.social
#MedSky
Antibiotics are not non-inferior to appendectomy despite a generous 20% non-inferiority margin
They are actually inferior: www.thelancet.com/journals/lan... in the @thelancet.bsky.social
#MedSky
January 17, 2025 at 3:06 AM
Finally!
Antibiotics are not non-inferior to appendectomy despite a generous 20% non-inferiority margin
They are actually inferior: www.thelancet.com/journals/lan... in the @thelancet.bsky.social
#MedSky
Antibiotics are not non-inferior to appendectomy despite a generous 20% non-inferiority margin
They are actually inferior: www.thelancet.com/journals/lan... in the @thelancet.bsky.social
#MedSky
Reposted by Jamie Willows
The efficacy and safety of half-dose glucocorticoids combined with #rituximab versus high-dose glucocorticoids for initial treatment of minimal change disease: a single-center experience
#nephsky
www.frontiersin.org/journals/pha...
#nephsky
www.frontiersin.org/journals/pha...
www.frontiersin.org
January 11, 2025 at 5:31 AM
The efficacy and safety of half-dose glucocorticoids combined with #rituximab versus high-dose glucocorticoids for initial treatment of minimal change disease: a single-center experience
#nephsky
www.frontiersin.org/journals/pha...
#nephsky
www.frontiersin.org/journals/pha...
Reposted by Jamie Willows
Proposed age-adjusted eGFR thresholds for CKD 👇
#Nephpearls #NephSky
eGFR 75 for ages <40 years
eGFR 60 for 40-65 years
eGFR 45 for >65 years
👉 link.springer.com/book/10.1007...
👉 pubmed.ncbi.nlm.nih.gov/31506289/
#Nephpearls #NephSky
eGFR 75 for ages <40 years
eGFR 60 for 40-65 years
eGFR 45 for >65 years
👉 link.springer.com/book/10.1007...
👉 pubmed.ncbi.nlm.nih.gov/31506289/
January 10, 2025 at 3:26 PM
Proposed age-adjusted eGFR thresholds for CKD 👇
#Nephpearls #NephSky
eGFR 75 for ages <40 years
eGFR 60 for 40-65 years
eGFR 45 for >65 years
👉 link.springer.com/book/10.1007...
👉 pubmed.ncbi.nlm.nih.gov/31506289/
#Nephpearls #NephSky
eGFR 75 for ages <40 years
eGFR 60 for 40-65 years
eGFR 45 for >65 years
👉 link.springer.com/book/10.1007...
👉 pubmed.ncbi.nlm.nih.gov/31506289/
Nice write-up of practise changing study by @osduvar.bsky.social for #nephjc
Meta-analysis of big name RCTs (AASK, IDNT, RENAAL etc) shows initiating RASi slows CKD progression even when already at stage 4 by more than I’d have guessed - just can’t believe no one had done this analysis before!
Meta-analysis of big name RCTs (AASK, IDNT, RENAAL etc) shows initiating RASi slows CKD progression even when already at stage 4 by more than I’d have guessed - just can’t believe no one had done this analysis before!
Is it ever too late to start RAS inhibitors in CKD?
www.nephjc.com/news/aceing-... from @osduvar.bsky.social
Join us this week to discuss on #NephJC
www.nephjc.com/news/aceing-... from @osduvar.bsky.social
Join us this week to discuss on #NephJC
ACEing the management of advanced CKD — NephJC
This week we come to meta-analyse, strikingly late, the cornerstone of all CKD treatments. Are you still in doubt? We need ACEing CKD to the end of GFR, and beyond
www.nephjc.com
December 17, 2024 at 1:24 PM
Nice write-up of practise changing study by @osduvar.bsky.social for #nephjc
Meta-analysis of big name RCTs (AASK, IDNT, RENAAL etc) shows initiating RASi slows CKD progression even when already at stage 4 by more than I’d have guessed - just can’t believe no one had done this analysis before!
Meta-analysis of big name RCTs (AASK, IDNT, RENAAL etc) shows initiating RASi slows CKD progression even when already at stage 4 by more than I’d have guessed - just can’t believe no one had done this analysis before!
Reposted by Jamie Willows
The UKKA AKI report is out, h/t @beckybonfield.bsky.social
@ukkidney.org
www.ukkidney.org/sites/defaul... (PDF)
Incl.
- Don’t call RAASi nephrotoxic
- Don’t delay contrast imaging
- Sick day rules are mostly 🐴 💩
@ukkidney.org
www.ukkidney.org/sites/defaul... (PDF)
Incl.
- Don’t call RAASi nephrotoxic
- Don’t delay contrast imaging
- Sick day rules are mostly 🐴 💩
December 13, 2024 at 11:47 AM
The UKKA AKI report is out, h/t @beckybonfield.bsky.social
@ukkidney.org
www.ukkidney.org/sites/defaul... (PDF)
Incl.
- Don’t call RAASi nephrotoxic
- Don’t delay contrast imaging
- Sick day rules are mostly 🐴 💩
@ukkidney.org
www.ukkidney.org/sites/defaul... (PDF)
Incl.
- Don’t call RAASi nephrotoxic
- Don’t delay contrast imaging
- Sick day rules are mostly 🐴 💩
Reposted by Jamie Willows
European Medicines Agency clears the way for Ozempic's label to list a kidney disease indication.
https://buff.ly/4fjah4b #ozempic #kidneydisease #nephsky
https://buff.ly/4fjah4b #ozempic #kidneydisease #nephsky
European Ozempic Label Will Include Kidney Disease Indication | Docwire News
The European label for Ozempic will be updated to include an indication for risk reduction for events related to kidney disease.
buff.ly
December 13, 2024 at 7:10 PM
European Medicines Agency clears the way for Ozempic's label to list a kidney disease indication.
https://buff.ly/4fjah4b #ozempic #kidneydisease #nephsky
https://buff.ly/4fjah4b #ozempic #kidneydisease #nephsky